Natural Products as a Paradigm for the Treatment of Coxsackievirus - induced Myocarditis

Author(s): Madhu Khanna*, Anju Gautam, Roopali Rajput, Latika Sharma.

Journal Name: Current Topics in Medicinal Chemistry

Volume 20 , Issue 8 , 2020

Become EABM
Become Reviewer

Graphical Abstract:


Coxsackievirus B3 (CVB3), a member of the Picornaviridae family, is considered to be one of the most important infectious agents to cause virus-induced myocarditis. Despite improvements in studying viral pathology, structure and molecular biology, as well as diagnosis of this disease, there is still no virus-specific drug in clinical use. Structural and nonstructural proteins produced during the coxsackievirus life cycle have been identified as potential targets for blocking viral replication at the step of attachment, entry, uncoating, RNA and protein synthesis by synthetic or natural compounds. Moreover, WIN (for Winthrop) compounds and application of nucleic-acid based strategies were shown to target viral capsid, entry and viral proteases, but have not reached to the clinical trials as a successful antiviral agent. There is an urgent need for diverse molecular libraries for phenotype-selective and high-throughput screening.

Keywords: Natural Products, Coxsackievirus, Myocarditis, Picornaviridae, Viral pathology, Antiviral agent.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2020
Page: [607 - 616]
Pages: 10
DOI: 10.2174/1568026620666200129094516
Price: $65

Article Metrics

PDF: 13